As in previous years, the consensus group to consider the use of biological agents in the
treatment of rheumatic diseases met during the 13th Annual Workshop on Advances in …

Monoclonal antibodies have emerged as a new class of agents causing drug-related
pulmonary involvement in patients with systemic rheumatologic autoimmune diseases. The …

As in previous years, the consensus group to consider the use of biological agents in the
treatment of rheumatic diseases met during the 11th Annual Workshop on Advances in …

As in previous years, the consensus group to consider the use of biological agents in the
treatment of rheumatic diseases met during the 13th Annual Workshop on Advances in …

Background Interstitial granulomatous dermatitis (IGD) is a rare disease for which a clinical–
pathological correlation is essential to establish diagnosis. Objectives To describe the …

As in previous years, the consensus group to consider the use of biological agents in the
treatment of rheumatic diseases met during the 12th Annual Workshop on Advances in …

Tumor necrosis factor (TNF)-α inhibitors (anti-TNF-α biologic drugs), currently used to treat
different autoimmune conditions, may be associated with cutaneous drug reactions. New …

Objectives To develop and/or update fact sheets about TNFα antagonists treatments, in
order to assist physicians in the management of patients with inflammatory joint disease …

Even though DIA has been known for many years, the underlying mechanisms remain
unclear. However, with recently described new and unexpected features, novel hypotheses …

TNF-α antagonists have been shown to be very effective for the treatment of various
rheumatic and nonrheumatic diseases, including psoriasis, and for off-label use in other …